tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Actinogen Medical Advances Alzheimer’s Trial and Secures R&D Funding

Story Highlights
Actinogen Medical Advances Alzheimer’s Trial and Secures R&D Funding

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Actinogen Medical ( (AU:ACW) ).

Actinogen Medical has reached a significant milestone in its XanaMIA phase 2b/3 clinical trial for Alzheimer’s disease, enrolling over 100 participants and planning an interim analysis in January 2026. Additionally, the company has secured a $13.8 million R&D tax incentive funding facility and completed a scale-up batch of Xanamem tablets, positioning itself for potential commercialization and partnerships.

More about Actinogen Medical

Actinogen Medical is a biotechnology company focused on developing innovative treatments for neurological conditions, particularly Alzheimer’s disease. The company is engaged in clinical trials and research to advance its primary product, Xanamem, which targets elevated blood biomarkers associated with Alzheimer’s.

Average Trading Volume: 7,733,709

Technical Sentiment Signal: Sell

Current Market Cap: A$79.43M

Find detailed analytics on ACW stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1